In recent years, the global radiopharmaceutical market has been booming rapidly. With its unique advantage of theranostics, Nuclear Medicine has gradually become a new focus in the medical field. In 2024, the transaction amount of radiopharmaceutical-related mergers and acquisitions agreements have exceeded 10 billion US dollars. Radiopharmaceuticals have shown great potential in the diagnosis and treatment of tumors, neurodegenerative diseases, metabolic diseases and other diseases. As the most promising development direction of nuclear medicine, RDC's diagnostic and treatment advantages and commercialization potential have driven global MNCs and local pharmaceutical companies to enter the market and compete for development.

Meanwhile with the Chinese government's attention and support for the field of nuclear medicine, especially after the introduction and implementation of policies and guidelines such as the "Medium- and Long-Term Development Plan for Medical Isotopes (2021-2035)", China’s nuclear medicine market has ushered in rapid development. According to Frost & Sullivan data, China's radioactive drug market for imaging diagnosis and treatment is expected to grow at a compound annual growth rate of 22.7% from 2025 to 2030, and the market size is expected to climb to 26 billion yuan by 2030. In the future, with the emergence of more radioactive nuclides and targets, more and more innovative nuclear medicines will move from research and development to clinical practice, and the improvement and maturation of the industrial chains and polices, the nuclear medicine market will continue to expand.

In view of this, the Targeted Radiopharmaceuticals Innovation Forum 2025 (TRPI2025) will gather leaders and scientists with the aim to facilitate the communication and partnership on the Frontier and Progress of Next-generation Targeted Radiopharmaceuticals, Early Discovery, Non-Clinical Development and Clinical Translation of Novel Diagnostic and Therapeutic Radiopharmaceuticals, Theranostics and Precision Medicine, Targeted Alpha Therapy and Emerging Medical Isotopes, Novel Targets and RDC, Dual-Targeted Radiopharmaceuticals and Combination Therapy, CMC Development, Manufacturing and Quality Control. 

TRPI2025 Conference Major Sessions/Topics

• Progress, Frontiers, Innovation and Cooperation in the Field of Targeted Radiopharmaceuticals
• Regulatory Policy and Strategies for Targeted Radiopharmaceuticals
• Theranostics and Precision Medicine
• Innovative Targets, Targeting Molecule Screening and Evaluation, Linker and Chelator Design
• Dual-Targeted Radiopharmaceuticals Research and Development
• Development of Innovative Diagnostic and Therapeutic Radiopharmaceuticals in the field of Oncology/Immuno-Oncology, CNS and Cardiovascular Diseases
• Targeted Alpha Therapy and Innovative Technology Platform
• Non-Clinical Research, Clinical and Translational Development
• Medical Isotopes Preparation and Supply
• CMC Development, Manufacturing and Quality Control
• Industry Investment/Financing and BD cooperation
  

Currently we are receiving the podium/poster abstracts. If you are working in the above areas, you are invited to submit a proposal.

For more information, please contact:

Wei Zhang
Program Manager
Organizing Committee
Email: wzhang@deliver-consulting.com
Phone: 86-21-5269-8916